Remove Compounding Remove Dosage Remove Process Improvement
article thumbnail

A Proposal for a Comprehensive Quality Overall Summary

ISPE

The TPP defines the indication and patient population, describes usage of the product, provides dosage and administration details, explains dosage form and strengths, and lists packaging and storage requirements. The results of the risk assessment are used to define experiments. CPP 3 IPC Film coat weight gain (P.3.4)

article thumbnail

A Proposal for a Comprehensive Quality Overall Summary

ISPE

The TPP defines the indication and patient population, describes usage of the product, provides dosage and administration details, explains dosage form and strengths, and lists packaging and storage requirements. The results of the risk assessment are used to define experiments. CPP 3 IPC Film coat weight gain (P.3.4)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Oligonucleotides: A Cornerstone for Therapeutics & More

ISPE

Broad pipelines require facilities to be designed with a large degree of flexibility to support anything from mild reaction conditions to the use of potent or highly biologically active compounds. Cone-bottom reaction vessels can provide the turndown required to process a variety of scales and handle different reactions.

article thumbnail

Considerations for a Decentralized Manufacturing Paradigm

ISPE

Examples include platforms as small as autonomous units placed within a facility and mobile production trailers for compounding to platforms as large as a prefabricated, self-contained GMP facility. POD is suitable for a wide range of products, including oral solid dosage forms, mAbs, and cell therapy. doi:10.1016/j.jbiotec.2015.06.388

article thumbnail

Regulatory Landscape for Raw Materials: CMC Considerations

ISPE

With shortages, regulatory complexity is compounded due to differences in submission and data requirements from various regulatory agencies. Quality Management Maturity for Finished Dosage Forms Pilot Program for Domestic Drug Product Manufacturers: Program Announcement.” Burke, PhD. 1 September 2022. 5 (May 2022): 1232–1244.